Locally advanced nasopharyngeal carcinoma
Conditions
Interventions
Experimental group:Nimotuzumab combined cisplatin, 5-fluorouracil neoadjuvant chemotherapy
Sponsors
The fourth affiliated hospital of Guangxi Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Newly diagnosed patients do not undergo radiotherapy, chemotherapy before clinical trials begin; 2) The histopathological diagnosis of nasopharyngeal carcinoma; 3) Clinical stage III-IVa (2008)/III b-IV stage (AJCC 2009); 4) There are measurable lesions by RECIST criteria; 5) Aged 18-70 years.
Exclusion criteria
Exclusion criteria: 1) Cognitive dysfunction; 2) Patients with distant metastases; 3) Patients with any other cancer in 5 years; 4) Any other disease or condition for chemotherapy and radiotherapy contraindications (such as active infection, myocardial infarction within 6 months, symptoms of heart disease, including unstable angina, congestive heart failure or arrhythmias that are not controlled, immunosuppressive therapy); 5) Women without using contraception during pregnancy and lactation,or fertility; 6) Bone marrow dysfunction; 7) Patients with bleeding tendency; 8) Drug abuse and alcohol addiction; 9) Patients having 3 or 4 allergic reactions for any drugs in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease remission rate;adverse reactions;overall survival; | — |
Countries
China
Contacts
Public ContactHai-xin HUANG
The fourth affiliated hospital of Guangxi Medical University
Outcome results
None listed